Skip to content
DraconiticResearch
Search Sources API
190,335 studies31 sourcesUpdated 4 min ago
Peer-reviewedCC BYDiagnostics (Basel, Switzerland)

Treatment-Stratified Immune–Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy

  • Ashley Kim1
  • Manaf Alsudaney1
  • Osama Khattab1
  • Daniel Legaspi1
  • Naomy Kim1
  • Shahzeb Imran2
  • Angelica E. Alderete3
  • Pin-Jung Chen4
  • Fadhil Jamil5
  • Jason Liu6
  • Jihye Lim7
  • Ekaterina Koltsova8
3 more authors
  • Walid Ayoub1
  • Andrew Hendifar4
  • Ju Dong Yang1
8 affiliations
  1. 1Department of Medicine, Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Cedars-Sinai Health Sciences University, Los Angeles, CA 90048, USA; (A.K.); (O.K.); (D.L.); (N.K.); (W.A.); (J.D.Y.)
  2. 2School of Medicine, Dentistry & Biomedical Sciences, , Belfast BT7 1NN, UK;
  3. 3Department of Enterprise Research Admin, Academic Affairs, Cedars-Sinai Health Sciences University, Los Angeles, CA 90048, USA;
  4. 4Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Health Sciences University, Los Angeles, CA 90048, USA; (P.-J.C.); (A.H.)
  5. 5Basic Medical Science, College of Medicine, , St. John’s P.O. Box W1451, Antigua and Barbuda;
  6. 6Chicago Medical School, , North Chicago, IL 60064, USA;
  7. 7The Catholic University Liver Research Center, College of Medicine, The , Seoul 06591, Republic of Korea;
  8. 8Cedars-Sinai Cancer, Department of Medicine, Cardiology and Biomedical Sciences, Cedars-Sinai Health Sciences University, Los Angeles, CA 90048, USA;
Read full textPDFCite

Related

  1. A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
    Saki Sueda, Tomokazu Kawaoka, Yasutoshi Fujii +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  2. Immune-mediated Myocarditis after Durvalumab/tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
    Shogo Mawatari, Ryu Sasaki, Yasuhiko Nakao +4
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedOncologyJ-STAGE
  3. An Effective Case of Radiofrequency Ablation with the Combination of Durvalumab and Tremelimumab Treatment for Hepatocellular Carcinoma
    Koji Rinka, Kiyohide Kioka, Rika Shioji +16
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  4. Systemic Treatment Versus No Systemic Treatment After Biliary Drainage in Patients with Icteric Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Chung-Wei Liu, Chi-Huan Wu, Yung-Kuan Tsou +3
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  5. Case Report: Long term multimodality treatment of canine hepatocellular carcinoma with serial monitoring of serum alpha-fetoprotein.
    Tae-Jung Dan, Cheol-Ho Yang, Yeon-Jin Kim +4
    Frontiers in veterinary sciencePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kim2026treatmentstratified,
  title = {{Treatment-Stratified Immune–Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy}},
  author = {Ashley Kim and Manaf Alsudaney and Osama Khattab and Daniel Legaspi and Naomy Kim and Shahzeb Imran and Angelica E. Alderete and Pin-Jung Chen and Fadhil Jamil and Jason Liu and Jihye Lim and Ekaterina Koltsova and Walid Ayoub and Andrew Hendifar and Ju Dong Yang},
  journal = {Diagnostics (Basel, Switzerland)},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13703371},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Treatment-Stratified Immune–Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy
AU  - Ashley Kim
AU  - Manaf Alsudaney
AU  - Osama Khattab
AU  - Daniel Legaspi
AU  - Naomy Kim
AU  - Shahzeb Imran
AU  - Angelica E. Alderete
AU  - Pin-Jung Chen
AU  - Fadhil Jamil
AU  - Jason Liu
AU  - Jihye Lim
AU  - Ekaterina Koltsova
AU  - Walid Ayoub
AU  - Andrew Hendifar
AU  - Ju Dong Yang
PY  - 2026
DA  - 2026/10/01
JO  - Diagnostics (Basel, Switzerland)
UR  - https://europepmc.org/article/PMC/PMC13703371
SN  - 2075-4418
ER  -